This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Why Bristol-Myers Squibb (BMY) Stock Is Down Today

NEW YORK (TheStreet) -- Bristol-Myers Squibb (BMY - Get Report) fell Tuesday after the pharmaceutical company reported mixed first-quarter earnings and announced it would seek FDA approval of its highly-anticipated drug nivolumab by the end of the year.

Bristol-Myers reported earnings of $937 million, or 56 cents a share, up from $609 million, or 37 cents a share, in the same period one year earlier. Excluding items, profit was 46 cents a share, which beat the estimate fo 43 cents from analysts polled by Thomson Reuters I/B/E/S.

But sales declined 1% year over year to $3.81 billion, which was approximately $80 million less than analysts' expectations.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Must Read: Warren Buffett's 10 Favorite Growth Stocks

The company's effective tax rate was 5%, down from 7.6% in the same period one year ago. Bristol-Myers increased the low end of its profit guidance to $1.70 a share, excluding items, from $1.65 and kept the high end at $1.80 for the full year.

Furthermore, Bristol-Myers intends to begin a rolling submission to the Food and Drug Administration for U.S. approval of nivolumab in patients with lung cancer that has proven difficult to treat. The submission would be completed by the end of the year, which is later than some analysts expected, according to  Bloomberg.
The stock was down 2.94% to $48.88 at 12:44 p.m.
BMY Chart

BMY data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BMY $70.39 -1.10%
AAPL $92.36 -0.95%
FB $118.98 0.99%
GOOG $707.86 0.92%
TSLA $215.49 1.90%


Chart of I:DJI
DOW 17,662.73 +2.02 0.01%
S&P 500 2,044.73 -5.90 -0.29%
NASDAQ 4,695.2610 -21.8330 -0.46%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs